Popular Trastuzumab News and Current Events

Popular Trastuzumab News and Current Events, Trastuzumab News Articles.
Sort By: Most Relevant | Most Recent
Page 1 of 7 | 261 Results
New drug combo improves survival of women with rare uterine cancer
Adding the monoclonal antibody drug trastuzumab -- already used to treat certain breast cancers -- to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small phase II trial of the regimen, testing its safety and value (2018-04-10)

New lab study reveals how breast cancer drug can accelerate cancer cell growth
The breast cancer drug lapatinib which is designed to shrink tumors can sometimes cause them to grow in the lab, according to a new study. By understanding the molecular basis of this phenomenon, scientists hope that their findings will lead to safer treatment decision-making and drug design in the future. (2018-05-01)

'I'm here for breast cancer. Why are you talking to me about my heart?'
Many physicians are not telling cancer patients about the cardiotoxicity risks of treatments and may not be fully aware of the dangers themselves. A new study reveals an urgent need to look after the hearts of these patients. The research is presented today at EuroHeartCare 2019, a scientific congress of the European Society of Cardiology. (2019-05-04)

Trastuzumab: No negative impact on cardiac function
Long-term follow-up results of the NRG Oncology trial NSABP B-31 have shown that the addition of trastuzumab to adjuvant chemotherapy does not negatively affect cardiac function in women with node-positive, human epidermal growth factor receptor 2 (HER2)-positive, early-stage breast cancer who survive without cancer recurrence. (2018-01-03)

Fewer breast cancer patients need radical surgery if they are pre-treated with targeted drugs
Extensive surgery involving mastectomy and removal of several lymph nodes can be safely avoided for more women with some types of breast cancer, if they receive targeted drugs before surgery, according to research presented at the 11th European Breast Cancer Conference. (2018-03-22)

HER2-targeted CAR T-cell therapy shows promising antitumor activity in patients with sarcoma
A combination of chemotherapy and chimeric antigen receptor (CAR) T cells designed to target the protein HER2 was found to be safe and showed clinical responses in pediatric and adult patients with advanced HER2-positive sarcoma, according to results from a phase I clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3. (2019-03-31)

Mayo Clinic researchers identify a potential new approach to treat HER2 positive breast cancer
Researchers at Mayo Clinic have identified an important new pathway by which HER2 positive breast cancers grow and have discovered that a dietary supplement called cyclocreatine may block the growth of HER2 positive breast cancer. Their findings were published today in Cell Metabolism. (2018-08-30)

HER2+ early breast cancers where shorter-course trastuzumab could be an option
Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich. (2018-10-19)

Will tarloxotinib finally break the HER2 barrier in lung cancer?
By pairing a potent HER2/EGFR inhibitor with a targeting mechanism specific to tumors, researchers show that tarloxotinib is far more active against HER2 lung cancer cell lines than even the most successful existing HER2/EGFR inhibitors. (2018-11-07)

Biosimilar for HER2+ breast cancer: Overall response rate matches reference trastuzumab
The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast cancer, according to a large, randomised phase III study reported at the ESMO Asia 2019 Congress. (2019-11-22)

Tucatinib 'game changing' against HER2+ breast cancer, especially with brain metastases
Phase III results at NEJM and SABCS: Adding tucatinib to standard of care treatment nearly tripled one-year progression-free survival. (2019-12-11)

Opening an autophagy window as the apoptosis door starts to close
Tokyo Medical and Dental University (TMDU) researchers have successfully attached the cancer cell-targeting antibody Trastuzumab to a previously reported supermolecule that induces autophagic cell death. The antibody-drug conjugate (ADC) selectively targeted HER2-overexpressing cancer calls and reduced cell viability at lower concentrations than free supermolecule drug. It is hoped that the ADC will provide a targeted autophagic death route for treating apoptosis resistant cancer cells in vivo, and ultimately provide an alternate approach in the clinic. (2020-09-24)

New type of drug shrinks primary breast cancer tumors significantly in just 6 weeks
A drug that targets the cell surface receptors that play an important role in many types of cancer can bring about significant tumor regression in breast cancer after only six weeks of use, a scientist told the 6th European Breast Cancer Conference on Thursday. Dr. Angel Rodriguez said that the work demonstrated for the first time that the tyrosine kinase inhibitor lapatinib could decrease tumor-causing breast cancer stem cells in the primary breast cancers of women receiving neoadjuvant treatment. (2008-04-17)

Scientists discover rogue messengers that hinder body's immune response to cancer
Researchers from Trinity College Dublin have made a discovery around treatment-resistant breast cancer that may turn the phrase, 'don't shoot the messenger', on its head. The scientists have found that cell to cell messengers released by cancer cells which are not responding to treatment, can negatively affect the body's immune system response against the cancer. They have also discovered a possible way for doctors to identify those patients most at risk of treatment resistance. (2017-09-27)

Statins may protect the heart from chemotherapy treatment of early breast cancer
Women who take statins, the common cholesterol-lowering medication, during chemotherapy with anthracyclines for early-stage breast cancer are half as likely to require emergency department visits or hospitalization for heart failure in the 5 years after chemotherapy. (2021-01-06)

Patients resistant to breast cancer therapy show epigenetic differences
According to a new study, breast cancer patients who don't respond to targeted therapy have different patterns of epigenetic modifications than patients who do respond. Epigenetic modifications change gene expression without altering the DNA's genetic code. (2019-04-06)

Breast cancer patients who take heart drug with trastuzumab have less heart damage
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a study presented today at EuroEcho-Imaging 2018. (2018-12-05)

DNA nanorobots target HER2-positive breast cancer cells
According to the Mayo Clinic, about 20% of breast cancers make abnormally high levels of a protein called human epidermal growth factor receptor 2 (HER2). When displayed on the surface of cancer cells, this signaling protein helps them proliferate uncontrollably and is linked with a poor prognosis. Now, researchers have developed a DNA nanorobot that recognizes HER2 on breast cancer cells, targeting them for destruction. They report their results in the ACS journal Nano Letters. (2019-06-05)

M. D. Anderson study finds change in HER2 status after treatment with Herceptin
Researchers at the University of Texas M. D. Anderson Cancer Center have discovered that when treated with Herceptin prior to surgery, 50 percent of HER2 positive, breast cancer patients showed no signs of disease at the time of surgery. However, of those women who had residual disease, about one-third had tumors that converted from HER2 positive to HER 2 negative status -- possibly indicating a resistance to the targeted therapy. (2008-09-03)

Surgery associated with increased survival for patients with HER2+ stage 4 breast cancer
Surgery was associated with higher survival rates for patients with HER2-positive (HER2+) stage 4 breast cancer compared with those who did not undergo surgery, according to results presented at the AACR Annual Meeting 2019, March 29-April 3. (2019-04-02)

Drug could alleviate side effects of chemo for breast cancer patients
Researchers at the Stanford University School of Medicine have demonstrated a method of forecasting which breast cancer patients will suffer heart problems from a commonly used chemotherapy drug. (2019-03-14)

Two-in-one drug combining Herceptin with chemotherapy keeps women's breast cancers at bay
Guiding chemotherapy to a tumor by attaching it to the antibody-based target drug Herceptin (trastuzumab) is effective at treating women with breast cancer who have no other treatment options, a new clinical trial shows. The two-in-one treatment kept breast cancer at bay in women with a type of the disease called HER2-positive breast cancer who had stopped responding to existing drugs. (2019-06-27)

A giant little step in cancer treatment opening up new therapeutic horizons
The study published today in the Journal of Clinical Oncology heralds a new horizon in the fight against cancer, opening up a parallel dimension to existing treatment options. (2012-02-27)

Combined therapy can reduce chance of recurrence in women with small, HER2+ breast tumors
Dana-Farber researchers report women with small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years. (2015-01-07)

Study: Prioritize cardiac monitoring for high-risk breast cancer patients
Overall, heart failure is an uncommon complication of breast cancer treatment; however, the risk is higher in patients treated with certain types of chemotherapy and lower in younger patients, according to a study in a special 'Imaging in Cardio-oncology' issue of JACC: Cardiovascular Imaging. Researchers concluded that cardiac monitoring should be a higher priority for high-risk patients. (2018-08-06)

New role for sugars: Research shows connections between sugar modifications in cells and cancer
In a ground-breaking study published in the top journal, Cell, Dr. James Dennis, senior investigator at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital, has discovered a new role for sugars on proteins. (2007-04-05)

Early biomarker for pancreatic cancer identified
Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease for which there is currently no reliable method for early detection or therapeutic intervention. (2012-05-15)

Dartmouth researchers discover new mechanism of acquired resistance to breast cancer drugs
In the search for new approaches to treat ERBB2 -- also known as HER2 -- positive breast cancers that have become drug-resistant, Dartmouth investigator Manabu Kurokawa, Ph.D., led a team in discovery of a novel cancer resistance mechanism. (2015-02-02)

HER2 positive breast cancer: Treatment de-escalation needs to be personalized
De-escalation approaches in the treatment of women with HER2 positive breast cancer need to be personalized, according to Dr. Carmen Criscitiello, European Institute of Oncology, Milan, Italy. Her comments come on the occasion of the presentation of updated research results at the inaugural ESMO Breast Cancer Congress 2019, May 2-4, 2019, in Berlin, Germany. (2019-05-01)

Phase III KATHERINE trial crossed early reporting boundary and met its primary endpoint
Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in patients who had residual disease after receiving neoadjuvant chemotherapy and trastuzumab reduced the risk of developing an invasive recurrence of HER2-positive early-stage breast cancer by 50 percent, according to data from the phase III clinical trial KATHERINE presented at the 2018 San Antonio Breast Cancer Symposium. (2018-12-05)

Simple and fast method for radiolabelling antibodies against breast cancer
Radioactive antibodies that target cancer cells are used for medical diagnostics with PET imaging or for targeted radioimmunotherapy. Researchers from the University of Zurich have created a new method for radiolabelling antibodies using UV light. In less than 15 minutes, the proteins are ready-to-use for cancer imaging or therapy. (2019-04-23)

Adding tucatinib to drug combination extends survival for advanced HER2+ breast cancer patients
Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial. (2019-12-11)

Trastuzumab treatment need not delay breast reconstruction following mastectomy
Treatment with trastuzumab (Herceptin/Genentech) of breast cancers that express the HER-2 protein does not increase the risk for complications at the surgical site for women who undergo immediate breast reconstruction after mastectomy. The first study to assess the effect of trastuzumab on surgical wound complications indicates that breast reconstruction need not be delayed because of the type or length of this form of adjuvant therapy. (2017-10-03)

Promising clinical trial results of tucatinib with T-DM1 against HER2+ breast cancer
Of 57 patients treated, 48 percent responded to the combination, with cancer control of median 8.2 months. (2018-07-10)

New molecule protects heart from toxic breast cancer drugs
A new molecule has been found that protects the heart from toxic breast cancer drugs and also kills the cancerous tumor. The research from Italy addresses the burgeoning problem of heart disease in cancer survivors and is announced by the European Society of Cardiology today on World Cancer Day. (2015-02-03)

Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
Fox Chase Cancer Center researchers report that a combination of trastuzumab and neratinib a novel small molecule inhibitor of the HER2 receptor appears active in women with HER2-positive metastatic breast cancer who have progressed on previous trastuzumab based therapies. More than one-quarter of the women in a phase I/II trial had their tumors shrink on the combination therapy. (2009-05-28)

Popular heart medications can prevent herceptin-induced heart issues in some patients
Breast cancer patients who started taking one of two well-known heart medications at the same time they initiated trastuzumab -- a targeted cancer therapy that has been linked to heart damage -- received no benefit in terms of preventing declines in heart function, according to research presented at the American College of Cardiology's 67th Annual Scientific Session. (2018-03-11)

Breast cancer patients receiving Herceptin treatment should be monitored for heart damage at any age
Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored for heart damage regardless of age. This is among the findings of a new study from the Peter Munk Cardiac Centre, the Institute for Clinical Evaluative Sciences and the Ted Rogers Centre for Heart Research, University Health Network. (2016-04-19)

Gene patenting -- steep cost for health care and patients
The drug trastuzumab (Herceptin) is used to treat HER2-positive breast cancer (a type of breast cancer that overexpresses the HER2 gene and accounts for about 25 percent of all breast cancers). Trastuzumab therapy improves the chances of survival; however, it has deleterious side effects and is expensive. Thus, it is important to accurately determine the patient's HER2 status. (2007-05-07)

Mayo Clinic researchers present findings at the 2019 San Antonio Breast Cancer Symposium
Mayo Clinic researchers will present findings at the San Antonio Breast Cancer Symposium Dec. 10-14 in San Antonio. (2019-12-13)

Page 1 of 7 | 261 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.